|
| Guidelines for the Management of Heavy Menstrual Bleeding |
| On September 30, 2004, Vioxx (rofecoxib) was withdrawn from the U.S. and worldwide market due to safety concerns of an increased risk of cardiovascular events. See the U.S. Food and Drug Administration (FDA) Web site for more information. Subsequently, on December 23, 2004, the FDA issued a public health advisory concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs) including the COX-2 selective agents Celebrex (celecoxib), Bextra (valdecoxib) and a non-selective NSAID, naproxen (sold as Aleve, Naprosyn and other trade name and generic products). See the FDA web site for more information . |
CME Quiz
|
| The Guidelines for Heavy Menstrual Bleeding CME quiz is available from "The CME Club".
Upon completion of the quiz you may 2 claim RNZCGP Advanced Vocational Education (AVE) / Maintenance of Professional Standards (MOPS) credits. You will need to print the certificate and keep it in a safe place to later submit to the Royal New Zealand College of General Practitioners as evidence that you have earned the credit.
|
|
|
« Back |
If you would like further information about this guideline, please contact the relevant organisation directly. Contact details are located in the 'Produced By' area on the homepage of this template. Please note that hard copies may no longer be available.
|
|
